These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37064133)

  • 1. Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study.
    Liu CG; Li YF; Ma TY; Lv M; Lv ZD; Wang YY; Liu XP; Mao Y; Wang HB
    Front Oncol; 2023; 13():1130734. PubMed ID: 37064133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
    Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
    Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (HER2)-low breast cancer: Compared with HER2-0 breast cancer.
    Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
    Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience.
    Xu H; Han Y; Wu Y; Wang Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Ma F; Xu B; Wang J
    Front Oncol; 2022; 12():906011. PubMed ID: 35785207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive/human epidermal growth factor receptor 2-low expression.
    Xin L; Wu Q; Zhan C; Qin H; Xiang H; Gao M; Duan X; Liu Y; Ye J; ;
    Chin Med J (Engl); 2023 Dec; 136(24):2967-2973. PubMed ID: 37822006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
    Chen Z; Jia H; Zhang H; Chen L; Zhao P; Zhao J; Fu G; Xing X; Li Y; Wang C
    Breast Cancer Res Treat; 2023 Nov; 202(2):313-323. PubMed ID: 37639064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
    Ergun Y; Ucar G; Akagunduz B
    Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying clinicopathological risk factors for regional lymph node metastasis in Chinese patients with T1 breast cancer: a population-based study.
    Liu G; Xing Z; Guo C; Dai Q; Cheng H; Wang X; Tang Y; Wang Y
    Front Oncol; 2023; 13():1217869. PubMed ID: 37601676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
    Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
    Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
    Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
    Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
    Lee SB; Sohn G; Kim J; Chung IY; Lee JW; Kim HJ; Ko BS; Son BH; Ahn SH
    Breast Cancer Res Treat; 2018 Jun; 169(2):257-266. PubMed ID: 29388016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of HER2-low expression in HER2-negative breast cancer under different hormone receptor status.
    Xu B; Shen J; Shen J; Wang L
    Int J Clin Oncol; 2023 Apr; 28(4):543-549. PubMed ID: 36723789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the primary tumor site and immune indexes in patients with estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Song X; Ma J; Zhang H; Zhang Q
    Gland Surg; 2020 Oct; 9(5):1450-1468. PubMed ID: 33224820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.
    Leone JP; Leone J; Zwenger AO; Vallejo CT; Leone BA
    Am J Clin Oncol; 2019 Jul; 42(7):588-595. PubMed ID: 31166208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.